Abstract
The decision of the appropriate treatment for pancreatic cystic lesions (PCLs) is becoming increasingly important as the number of incidentally found PCLs increases. A range of modalities have been attempted because there has been an increasing demand for minimally invasive treatment for PCLs due to the large burden of a surgical resection. Endoscopic treatment using endoscopic ultrasonography (EUS), a representative of minimally invasive therapy, can be categorized into two types: ablation therapy by the injection of drugs and topical thermal coagulative therapy through the high topical energy. A number of studies reported the feasibility and efficacy of these treatments; the most common is EUS-guided ablation for PCLS with ethanol alone or in combination with anticancer drugs. Although ablation therapies with drug injection have proven safety and feasibility, there is no consensus regarding the actual treatment effects and indications of these modalities. EUS-guided radiofrequency ablation was recently attempted as a representative method of local thermal coagulation, but further studies will be needed because of the lack of evidence of its feasibility and safety. In addition, a range of treatments for malignant tumors rather than PCLs have been attempted, such as EUS-guided photodynamic therapy, EUS-guided neodymium-doped yttrium aluminum garnet laser, and high-intensity focused ultrasound, based on the data from animal experiments. Through further study, endoscopic treatment is expected to become established as a useful treatment modality for PCLs.
Figures and Tables
Table 1
BD-IPMN, branch duct type intraductal papillary mucinous neoplasm; CA 19-9, carbohydrate antigen 19-9; CT, computed tomography; MRI, magnetic resonance imaging; EUS, endoscopic ultrasonography.
aConsider surgery in young, fit patients with need for prolonged surveillance; bStrongly consider surgery in young, fit patients.
References
1. Stark A, Donahue TR, Reber HA, Hines OJ. Pancreatic cyst disease: a review. JAMA. 2016; 315:1882–1893.
2. Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17:738–753.
3. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012; 12:183–197.
4. Vege SS, Ziring B, Jain R, Moayyedi P. Clinical Guidelines Committee. American Gastroenterology Association. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148:819–822. quize12-13.
5. Choi JH, Seo DW, Song TJ, et al. Long-term outcomes after endoscopic ultrasound-guided ablation of pancreatic cysts. Endoscopy. 2017; 49:866–873.
6. Park JK, Song BJ, Ryu JK, et al. Clinical outcomes of endoscopic ultrasonography-guided pancreatic cyst ablation. Pancreas. 2016; 45:889–894.
7. Moyer MT, Sharzehi S, Mathew A, et al. The safety and efficacy of an alcohol-free pancreatic cyst ablation protocol. Gastroenterology. 2017; 153:1295–1303.
8. Gómez V, Takahashi N, Levy MJ, et al. EUS-guided ethanol lavage does not reliably ablate pancreatic cystic neoplasms (with video). Gastrointest Endosc. 2016; 83:914–920.
9. Gelczer RK, Charboneau JW, Hussain S, Brown DL. Complications of percutaneous ethanol ablation. J Ultrasound Med. 1998; 17:531–533.
10. Gan SI, Thompson CC, Lauwers GY, Bounds BC, Brugge WR. Ethanol lavage of pancreatic cystic lesions: initial pilot study. Gastrointest Endosc. 2005; 61:746–752.
11. DeWitt J, McGreevy K, Schmidt CM, Brugge WR. EUS-guided ethanol versus saline solution lavage for pancreatic cysts: a randomized, double-blind study. Gastrointest Endosc. 2009; 70:710–723.
12. DiMaio CJ, DeWitt JM, Brugge WR. Ablation of pancreatic cystic lesions: the use of multiple endoscopic ultrasound-guided ethanol lavage sessions. Pancreas. 2011; 40:664–668.
13. Caillol F, Poincloux L, Bories E, et al. Ethanol lavage of 14 mucinous cysts of the pancreas: a retrospective study in two tertiary centers. Endosc Ultrasound. 2012; 1:48–52.
14. Kandula M, Moole H, Cashman M, Volmar FH, Bechtold ML, Puli SR. Success of endoscopic ultrasound-guided ethanol ablation of pancreatic cysts: a meta-analysis and systematic review. Indian J Gastroenterol. 2015; 34:193–199.
15. Oh HC, Seo DW, Lee TY, et al. New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc. 2008; 67:636–642.
16. Oh HC, Seo DW, Song TJ, et al. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. Gastroenterology. 2011; 140:172–179.
17. DeWitt JM, Al-Haddad M, Sherman S, et al. Alterations in cyst fluid genetics following endoscopic ultrasound-guided pancreatic cyst ablation with ethanol and paclitaxel. Endoscopy. 2014; 46:457–464.
18. Moyer MT, Dye CE, Sharzehi S, et al. Is alcohol required for effective pancreatic cyst ablation? The prospective randomized CHARM trial pilot study. Endosc Int Open. 2016; 4:E603–E607.
19. Paiella S, Salvia R, Ramera M, et al. Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation): a review. Gastroenterol Res Pract. 2016; 2016:4508376.
20. Signoretti M, Valente R, Repici A, Delle Fave G, Capurso G, Carrara S. Endoscopy-guided ablation of pancreatic lesions: technical possibilities and clinical outlook. World J Gastrointest Endosc. 2017; 9:41–54.
21. Pai M, Habib N, Senturk H, et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg. 2015; 7:52–59.
22. Barthet M, Giovannini M, Lesavre N, et al. UEG week 2017 oral presentations-OP 315: EUS-guided radiofrequency ablation (RFA) for pancreatic neuroendocrine tumor (NET) and pre-malignant intraductal pancreatic mucinous tumor (IPMN): first results of prospective multicenter study. United European Gastroenterol J. 2017; 5:Suppl. A1–A160.
23. Song TJ, Seo DW, Lakhtakia S, et al. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc. 2016; 83:440–443.
24. Choi JH, Lee SH, Kim JS, et al. PBS24-comparison of natural course versus EUS-guided ethanol ablation for pancreatic cystic lesions. In : Proceedings of the 66th congress of the Korean Society of Gastrointestinal Endoscopy; Seoul, Korea: 2016.
25. Choi JH, Lee SH, Choi YH, et al. PB2-safety and adverse events of EUS-guided ethanol ablation for pancreatic cystic lesions: a single center experience with 188 patients. In : Proceedings of the 1st Korea Digestive Disease Week (KDDW); Seoul, Korea: 2017.
26. Arcidiacono PG, Carrara S, Reni M, et al. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc. 2012; 76:1142–1151.
27. Chan HH, Nishioka NS, Mino M, et al. EUS-guided photodynamic therapy of the pancreas: a pilot study. Gastrointest Endosc. 2004; 59:95–99.
28. Yusuf TE, Matthes K, Brugge WR. EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video). Gastrointest Endosc. 2008; 67:957–961.
29. Choi JH, Oh D, Lee JH, et al. Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter. Endoscopy. 2015; 47:1035–1038.
30. Di Matteo F, Martino M, Rea R, et al. US-guided application of Nd:YAG laser in porcine pancreatic tissue: an ex vivo study and numerical simulation. Gastrointest Endosc. 2013; 78:750–755.
31. Di Matteo F, Martino M, Rea R, et al. EUS-guided Nd:YAG laser ablation of normal pancreatic tissue: a pilot study in a pig model. Gastrointest Endosc. 2010; 72:358–363.
32. Sofuni A, Moriyasu F, Sano T, et al. Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. World J Gastroenterol. 2014; 20:9570–9577.